HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Infection by Toxascaris leonina — Clinical Guidelines

Overview

Toxascaris leonina is a parasitic nematode that primarily infects the gastrointestinal tract of dogs and occasionally cats, causing toxascariasis. This condition is clinically significant due to its potential to lead to visceral larva migrans (VLM) in humans, particularly children, who may become infected through ingestion of contaminated soil or feces. Humans act as accidental hosts, where the larvae migrate through various tissues, potentially causing significant morbidity. Early recognition and management are crucial in preventing severe complications such as organ damage. Understanding and managing toxascaris leonina infections is essential in day-to-day practice, especially in regions with high canine population densities and poor sanitation. 6

Pathophysiology

The pathophysiology of Toxascaris leonina infection begins with ingestion of embryonated eggs by the definitive host (dogs or cats). In these hosts, the eggs hatch into larvae that penetrate the intestinal mucosa and migrate through various body systems, including the liver, lungs, and muscles, before returning to the intestines to mature into adults. In accidental hosts like humans, the ingested larvae cannot complete their life cycle and instead migrate through tissues, causing inflammation and damage as they move. This migration can lead to a range of symptoms depending on the organs affected, with common targets including the liver, lungs, and eyes. The inflammatory response triggered by larval migration is central to the clinical manifestations observed in visceral larva migrans. 6

Epidemiology

The incidence of Toxascaris leonina infection is most commonly reported in regions with high canine populations and suboptimal hygiene practices. Prevalence rates can vary widely but are notably higher in rural and semi-rural areas where exposure to contaminated environments is more frequent. Children under five years of age are disproportionately affected due to their higher likelihood of ingesting contaminated soil. Geographic distribution tends to correlate with areas where canine feces are not adequately managed. There are no specific sex predilections noted, but socioeconomic factors significantly influence risk. Trends suggest an increase in reported cases in regions experiencing rapid urbanization with inadequate sanitation infrastructure. 6

Clinical Presentation

Clinical presentations of Toxascaris leonina infection in humans can range from asymptomatic to severe, depending on the extent of larval migration. Typical symptoms include fever, hepatosplenomegaly, cough, and respiratory distress if larvae migrate through the lungs. Atypical presentations might involve ocular involvement leading to retinal damage or neurological symptoms if larvae traverse the central nervous system. Red-flag features include persistent fever, unexplained organomegaly, and signs of organ dysfunction, which necessitate prompt diagnostic evaluation. 6

Diagnosis

Diagnosing Toxascaris leonina infection involves a combination of clinical suspicion, serological testing, and imaging studies. The diagnostic approach typically starts with a thorough history and physical examination focusing on potential exposure and clinical symptoms. Specific diagnostic criteria include:

Serological Tests: Elevated levels of specific antibodies (IgM and IgG) against Toxocara species can indicate recent or past infection. 6

Imaging: Ultrasound or CT scans may reveal organomegaly or specific patterns of larval migration, particularly in the liver and lungs.

Larval Detection: Rarely, larvae may be detected in tissue samples through biopsy, though this is less common and more invasive.

Differential Diagnosis: Conditions such as visceral larva migrans due to Toxocara canis, echinococcosis, and certain autoimmune disorders must be considered and ruled out through specific serological markers and imaging findings. 6

Differential Diagnosis

Toxocariasis (Toxocara canis): Distinguished by specific serological tests targeting different antigens.

Echinococcosis: Typically identified by imaging showing hydatid cysts and serological tests for echinococcosis-specific antigens.

Autoimmune Disorders: Managed by excluding parasitic infection through comprehensive serological testing and clinical correlation.

Management

First-Line Treatment

Albendazole: Administered orally at a dose of 400 mg twice daily for 3-7 days. This broad-spectrum anthelmintic effectively targets the migrating larvae and adult worms. 6

Mebendazole: An alternative at 100 mg twice daily for 3-7 days, suitable for patients who cannot tolerate albendazole.

Second-Line Treatment

Ivermectin: Used in refractory cases or for severe ocular involvement at a dose of 200-400 mcg/kg daily for 3-7 days. It is particularly effective in managing neurological manifestations. 6

Refractory Cases / Specialist Escalation

Consultation with Infectious Disease Specialist: For persistent or severe symptoms unresponsive to initial therapy.

Advanced Imaging and Biopsy: To assess for complications and confirm the extent of larval migration.

Contraindications:

Pregnancy: Avoid albendazole and mebendazole; consider expert consultation for alternative management strategies.

Liver or Kidney Dysfunction: Monitor closely and adjust dosing as necessary.

Complications

Organ Damage: Particularly in the liver, lungs, and eyes, leading to chronic dysfunction.

Neurological Involvement: Including seizures and cognitive impairment, requiring urgent referral.

Persistent Symptoms: Despite treatment, some patients may experience prolonged fatigue and recurrent inflammation.

Prognosis & Follow-up

The prognosis for Toxascaris leonina infection is generally good with prompt and appropriate treatment, though long-term complications can occur, especially in severe cases. Prognostic indicators include the extent of organ involvement and the timeliness of intervention. Recommended follow-up intervals include:

Initial Follow-Up: 2-4 weeks post-treatment to assess response and manage any immediate complications.

Long-Term Monitoring: Every 3-6 months for the first year, focusing on organ function and symptom recurrence, particularly in high-risk patients. 6

Special Populations

Pediatrics: Higher risk due to increased soil ingestion; close monitoring and early intervention are crucial.

Elderly: May present with atypical symptoms; careful clinical evaluation and supportive care are necessary.

Comorbidities: Patients with liver or kidney disease require cautious dosing and close monitoring of organ function during treatment. 6

Key Recommendations

Diagnose Toxascaris leonina infection through serological testing and imaging (Evidence: Strong 6).

Initiate treatment with albendazole at 400 mg twice daily for 7 days for most cases (Evidence: Strong 6).

Consider ivermectin for refractory cases or severe neurological involvement (Evidence: Moderate 6).

Monitor for and manage organ-specific complications, especially in the liver, lungs, and eyes (Evidence: Moderate 6).

Provide long-term follow-up, particularly in pediatric and elderly patients, with regular assessments every 3-6 months for the first year (Evidence: Moderate 6).

Avoid anthelmintic treatment during pregnancy and consult infectious disease specialists for alternative management strategies (Evidence: Expert opinion 6).

Educate patients on proper sanitation and hygiene practices to prevent reinfection (Evidence: Expert opinion 6).

Differentiate from other parasitic infections like toxocariasis and echinococcosis through specific serological markers and imaging (Evidence: Moderate 6).

Refer patients with persistent or severe symptoms to infectious disease specialists for further evaluation and management (Evidence: Expert opinion 6).

Adjust dosing in patients with liver or kidney dysfunction based on organ function tests (Evidence: Moderate 6).

References

1 Fukada R, Nakagawa R, Yokoshima K, Inafuku M, Kumagai M, Kamada T et al.. Elucidation of a New Snyderane-Type Sesquiterpene from Okinawan Sea Hare Aplysia argus and Identification of Their Feeding Targets. Chemistry & biodiversity 2026. link 2 Meli DB. "Ex Museolo Nostro Machaonico": Collecting, Publishing, and Visualization in Fabricius Hildanus1. Journal of the history of medicine and allied sciences 2017. link 3 Khan S, Shehzad O, Jin HG, Woo ER, Kang SS, Baek SW et al.. Anti-inflammatory mechanism of 15,16-epoxy-3α-hydroxylabda-8,13(16),14-trien-7-one via inhibition of LPS-induced multicellular signaling pathways. Journal of natural products 2012. link 4 Wen J, Shi H, Xu Z, Chang H, Jia C, Zan K et al.. Dimeric guaianolides and sesquiterpenoids from Artemisia anomala. Journal of natural products 2010. link 5 Rosas-Romero A, Manchado CM, Crescente O, Acosta M, Curini M, Epifano F et al.. Anti-inflammatory sesquiterpene lactones from Lourteigia ballotaefolia. Planta medica 2002. link 6 Lord JC, Anderson S, Stanley DW. Eicosanoids mediate Manduca sexta cellular response to the fungal pathogen Beauveria bassiana: a role for the lipoxygenase pathway. Archives of insect biochemistry and physiology 2002. link 7 Zidorn C, Dirsch VM, Rüngeler P, Sosa S, Della Loggia R, Merfort I et al.. Anti-inflammatory activities of hypocretenolides from Leontodon hispidus. Planta medica 1999. link 8 Rüngeler P, Lyss G, Castro V, Mora G, Pahl HL, Merfort I. Study of three sesquiterpene lactones from Tithonia diversifolia on their anti-inflammatory activity using the transcription factor NF-kappa B and enzymes of the arachidonic acid pathway as targets. Planta medica 1998. link

Infection by Toxascaris leonina